Jump to content

User:Mjhopkins81/ADAP Advocacy

From Wikipedia, the free encyclopedia

ADAP Advocacy
FormationJuly 6, 2007; 17 years ago (2007-07-06)
FoundersGary Rose
John D. Kemp, Esq.
Joyce Turner Keller
Keita Simmons
Philip A. Haddad, MD
Rani G. Whitfield, MD
William E. Arnold
Founded atWashington, D.C.
Type 501(c)(3) Nonprofit Organization
26-0482120
Legal statusCharity
PurposePromote and enhance the AIDS Drug Assistance Programs (ADAPs)
Improve access to care for Persons Living With HIV/AIDS (PLWHA)
HeadquartersNags Head, NC
Region served
United States
U.S. Territories
ProductsADAP Blog
ADAP Directory
CEO
Brandon M. Macsata
Guy Anthony
Wanda Brendle-Moss, RN
Erin Darling, Esq
Robert "Bobby" Dorsey, Esq.
Eric Flowers
Lyne Fortin, B.Pharm, MBA
Hilary Hansen
Lisa Johnson-Lett
Jen Laws
Brandon M. Macsata
Theresa Nowlin
Shabbir Imber Safdar
Jennifer Vaughan
Marcus A. Wilson
Websitewww.adapadvocacy.org
Formerly called
ADAP Advocacy Association

ADAP Advocacy is a national 501(c)(3) non-profit organization based in Washington, D.C., that is dedicated to promoting and enhancing the AIDS Drug Assistance Programs (ADAPs) and improving access to care and treatment for Persons Living with HIV/AIDS (PLWHA) in the United States and the U.S. Territories.[1]

History

[edit]

ADAP Advocacy (formerly the ADAP Advocacy Association, or aaa+) began as an organizing committee in 2007 comprised of advocates, community leaders, students, medical specialists, and ADAP recipients in response to the then long-standing waiting list crisis facing the Ryan White HIV/AIDS Program (RWHAP), commonly known as the ADAP Crisis.[2] [3] [4] The ADAP Crisis resulted in tens of thousands of Persons Living with HIV/AIDS (PLWHA) being unable to access life-saving medications to treat their HIV across the United States, peaking in September 2011 with 9,298 individuals on ADAP waiting lists.[5]

Throughout most of the 2000s and early 2010s, state ADAPs were forced to place financially eligible PLWHA on waiting lists to receive financial assistance to afford life-saving medications to treat HIV.[6] [7] [8] [9] [10] These waiting lists were largely the result of insufficient federal funding to keep up with the demand for ADAP services by new potential patients through the congressional appropriations process through which state ADAPs are funded.

ADAP Advocacy, in collaboration with the AIDS Healthcare Foundation, Community Access National Network (CANN), and Housing Works, pushed the introduction of federal legislation to re-appropriate funding to State AIDS Drug Assistance Programs.[11] The legislation, S.3401,[12] introduced by former Senator Richard Burr, proposed using unobligated Stimulus dollars to address AIDS Drug Assistance Program waiting lists and other cost containment measures impacting people living with HIV/AIDS.[13]

The organization hosted an Emergency Summit in Florida,[14] which was the epicenter of the beginning of the ADAP Crisis,[15] culminating in advocates sending a letter[16] to then President Barack Obama demanding action.[17] The Summit also paved the way for significant concessions from industry partners to help alleviate fiscal pressures on ADAPs.[18]

During the ADAP Crisis that landed thousands of PLWHA living in the United States across 13 states on ADAP waiting lists for their life-saving medications, ADAP Advocacy published a Congressional Scorecard evaluating Members of Congress on their commitment to fighting HIV/AIDS.[19] The scorecard was discontinued in 2014.

ADAP Directory

[edit]

On August 14th, 2014, ADAP Advocacy announced the launch of the AIDS Drug Assistance Program Directory (a.k.a., the ADAP Directory),[20] a website that allows users to find information about each of the 60 state and territorial ADAPs, including:

  • Eligibility criteria;
  • Application instructions;
  • Full-Pay formulary coverage;
  • If the program covers curative Hepatitis C Direct-Acting Antivirals;
  • If the program covers newer long-acting injectable antiretroviral medications, and;
  • Contact information for each program[21]

While other organizations, including the National Alliance of State and Territorial AIDS Directors,[22] had created other ADAP information databases, those tools had generally been developed with state- and program-level administrative staff persons in mind. The development and release of the ADAP Directory represented the first time that a comprehensive patient-centric database of information was made available.

Advocacy Work

[edit]

While ADAP Advocacy primarily focuses on issues related specifically to state ADAPs the federal appropriations associated with them, their work has also extended to into other issues related to access to HIV care and treatment, and public health, including:

The 340B Drug Pricing Program is U.S. federal program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. Those covered entities then receive the difference between the reduced prices and the list prices for 340B eligible drugs in the form of rebates that count as revenue.[23]

ADAP Advocacy has long advocated for changes to the 340B program in order to address what many patients, advocates, and drug manufacturers deem abuses by 340B covered entities.[24] [25] [26] [27]

In November 2022, ADAP Advocacy formed the Ryan White Grantee 340B Patient Advisory Committee in order to address gaps in knowledge and awareness among patients, advocates, providers, organizations, and industry partners about the 340B Program.[28] The advisory committee first convened in January 2023 and meets quarterly.

In addition to the advisory committee, research conducted by the ADAP Advocacy found that hospitals who were eligible for 340B rebates saw significant increases in revenues and CEO compensation while simultaneously decreasing the amount of charity care they provided to patients.[29]

ADAP Advocacy is dedicated to raising awareness of counterfeit prescription medications. Brandon Macsata, CEO of ADAP Advocacy, uses both his personal experience of importing potentially counterfeit HIV medications through a Canadian online pharmacy in 2002[31] and scientific data from federal agencies, including the Centers for Disease Control and Prevention (CDC),[32] and drug manufacturers[33] [34] to inform patients of the dangers related to counterfeit medications.

ADAP Advocacy has developed public service announcements (PSAs),[35] blog posts,[36] op-eds,[37] [38] and interviews with press outlets[39] in an effort educate patients about the risks of and how to identify counterfeit medications.

In addition to its own work, ADAP Advocacy has partnered with the Partnership for Safe Medicines (PSM), a public health group composed of more than 45 non-profit organizations, to address issues related to counterfeit medications.[40]

ADAP Advocacy's other advocacy work has included:

  • Prescription drug importation
  • Affordable Care Act’s impact on Ryan White CARE Act programs
  • Medicare-related issues
  • HIV/AIDS clinical care guidelines
  • COVID-19[41]
  • Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV transmission
  • HIV care for transgender populations
  • HIV care for incarcerated populations
  • Long-Acting Injectable (LAI) medications for the treatment of HIV and HIV-related conditions[42]

References

[edit]
  1. ^ "About Us". ADAP Advocacy. 2023. Retrieved November 3, 2023.
  2. ^ "Waiting for AIDS Medications in the United States: An Analysis of ADAP Waiting Lists" (PDF). Kaiser Family Foundation. December 2004. Retrieved November 3, 2023.
  3. ^ Saag, M. S. (November 15, 2006). "Which Policy to ADAP-T: Waiting Lists or Waiting Lines?". Clinical Infectious Diseases. 43 (10): 1356–167. doi:10.1086/508664.
  4. ^ Allen, B. (July 8, 2010). "What does an ADAP waiting list really mean? A look at the deepening crisis from HIV/AIDS Service Organizations' point of view". The Body Pro. Retrieved November 3, 2023.
  5. ^ "AIDS Drug Assistance Programs (ADAPs)" (Issue Brief). KFF. August 16, 2017. Retrieved November 16, 2023.
  6. ^ Cross, L. (May 1, 2011). "The ADAP Crisis: Waiting for Meds" (Article). The Body Pro. Retrieved November 16, 2023.
  7. ^ Straube, T. (June 30, 2010). "ADAP SOS" (Article). POZ. Retrieved November 16, 2023.
  8. ^ Blow, C. M. (May 13, 2011). "H.I.V. SOS" (Op-Ed). The New York Times. Retrieved November 16, 2023.
  9. ^ Lombino, E. (February 2, 2011). "The AIDS Drug Assistance Program Crisis in America" (Article). Retrieved November 16, 2023.
  10. ^ Fair Pricing Coalition (April 15, 2010). "An Open Letter to Pharmaceutical Companies on the ADAP Crisis" (Open Letter). The Body Pro. Retrieved November 16, 2023.
  11. ^ Pecquet, J. "Administration to unveil national AIDS strategy amid frustrations of advocates". The Hill. The Hill. Retrieved November 16, 2023.
  12. ^ "S.3401" (PDF). Retrieved November 16, 2023.
  13. ^ ADAP Advocacy. "ADAP Advocacy Association Urges Congress to Pass S.3401; Legislation introduced by Senator Richard Burr uses unobligated Stimulus dollars to address AIDS Drug Assistance Program waiting lists and other cost containment measures impacting people living with HIV/AIDS" (Press Release).
  14. ^ Florida Independent (January 19, 2016). "AIDS Drug Assistance Program activists schedule 'crisis' summit to find solutions for budget hole: News. Politics. Media" (Article). Retrieved November 16, 2023.
  15. ^ Horn, T. "Fiasco in Florida". POZ. POZ. Retrieved November 16, 2023.
  16. ^ "ADAP Crisis Sign-On Letter to Jeffrey Crowley, Director, Office of National AIDS Policy" (PDF). ADAP Advocacy. Retrieved November 16, 2023.
  17. ^ "U.S. HIV/AIDS Community Activist Sign-On Letter Presses Obama, Congress for ADAP Funds" (Press Release). TheBodyPro. HealthCentral, LLC. Retrieved November 16, 2023.
  18. ^ "Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV" (Press Release). Merck. Retrieved November 16, 2023.
  19. ^ ADAP Advocacy (February 7, 2011). "ADAP Advocacy Association Releases 2010 Congressional Scorecard; Legislative Gridlock Leads to Failing Grade for Entire Congress" (Press Release). HealthAccess, LLC. TheBodyPro. Retrieved November 16, 2023.
  20. ^ ADAP Advocacy (August 4, 2014). "ADAP Advocacy Association Launches Comprehensive ADAP Directory; Flagship Program is Designed to Link Patients to Information about AIDS Drug Assistance Programs" (Press Release). Retrieved November 16, 2023.
  21. ^ "About". ADAP Directory. 2023. Retrieved November 16, 2023.
  22. ^ National Alliance of State and Territorial AIDS Directors (2023). "Member Directory". Retrieved November 15, 2023.
  23. ^ The Commonwealth Fund (September 8, 2022). "The Federal 340B Drug Pricing Program: What It Is, and Why It's Facing Legal Challenges" (Explainer). Retrieved November 16, 2023.
  24. ^ ADAP Advocacy; Community Access National Network (October 1, 2020). "Industry's Proposed Changes to 340B Drug Discount Program" (Dear Colleague Letter). Retrieved November 16, 2023.
  25. ^ Macsata, B. M.; Anthony, G. (June 7, 2023). "What's Needed to Fix a Vital Drug Discount Program" (Op-Ed). POZ. Retrieved November 16, 2023.
  26. ^ Glassman, J. K. (July 18, 2023). "Health care providers are raking in profits by exploiting programs meant for the poor" (Op-Ed). The Hill. Retrieved November 16, 2023.
  27. ^ Macsata, B. M.; Laws, J. (September 23, 2023). "340B Hypocrisy: The inconvenient truth behind why we need to reform this vital safety net program" (Op-Ed). Positively Aware. Retrieved November 16, 2023.
  28. ^ ADAP Advocacy (November 16, 2022). "ADAP Advocacy Association Launches Ryan White Grantee 340B Project" (Press Release). Retrieved November 17, 2023.
  29. ^ Newton, W. (November 2, 2023). "340B Program May Lead to Lower Charity Care, Says Drug Industry-Backed AIDS Group" (Article). Retrieved November 16, 2023.
  30. ^ The Partnership for Safe Medicines (April 5, 2022). "Partnership For Safe Medicines Releases Anti-Counterfeit Public Service Announcement With ADAP Advocacy Association" (Press Release). Retrieved November 16, 2023.
  31. ^ Macsata, B. M. (August 11, 2017). "Drug importation policy is a hard pill to swallow" (Op-Ed). The Washington Blade. Retrieved November 17, 2023.
  32. ^ O'Donnell, J.; Tanz, L. J.; Miller, K. M.; Dinwiddie, A. T.; Wolff, J.; Mital, S.; Obiekwe, R.; Mattson, C. L. (September 1, 2023). "Drug Overdose Deaths with Evidence of Counterfeit Pill Use — United States, July 2019–December 2021". Morbidity and Mortality Weekly Report. 75 (35). Atlanta, Georgia, USA: Centers for Disease Control and Prevention: 949–956. Retrieved November 17, 2023.
  33. ^ Janssen (December 24, 2020). "Janssen Alerts Counterfeit SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide) is Being Distributed in the United States" (Media Statement). Retrieved November 17, 2023.
  34. ^ Gilead Sciences, Inc. (August 5, 2021). "Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States" (Press Release). Retrieved November 17, 2023.
  35. ^ "ADAP ADVOCACY PSA COMBAT COUNTERFEIT DRUGS - Brandon M. Macsata" (Video). YouTube. ADAP Advocacy. March 11, 2022. Retrieved November 17, 2023.
  36. ^ Hopkins, M. J. (October 26, 2023). "A Growing Problem, which is Potentially Contributing to Overdose Deaths" (Blog Post). Retrieved November 17, 2023.
  37. ^ Macsata, B. M. (March 6, 2019). "GUEST COMMENTARY: Imported medication might be fake" (Op-Ed). The Times of Northwest Indiana. Retrieved November 17, 2023.
  38. ^ Macsata, B. M. (November 1, 2022). "How Drug Imports Can Endanger Patients" (Op-Ed). International Business Times. Retrieved November 17, 2023.
  39. ^ Shelly, E. (September 12, 2022). "Counterfeit HIV Meds Are Endangering Some of America's Most Vulnerable People" (Interview). Retrieved November 17, 2023.
  40. ^ "About The Partnership For Safe Medicines" (Website). The Partnership for Safe Medicines. 2023. Retrieved November 17, 2023.
  41. ^ Robbins, J. "#YourVaccineIsWaiting Campaign Launches by ADAP Advocacy Association" (Blog Post). Retrieved November 16, 2023.
  42. ^ ADAP Advocacy (2023). "Publications". Retrieved November 15, 2023.
[edit]

ADAP Advocacy

ADAP Directory

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mjhopkins81/ADAP_Advocacy&oldid=1185594353"